An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan

Oncology (Switzerland)

Volumn 84, Issue 5, 2013, Pages 299-304

  Lee, Kuan Der ^a,b   Chen, Hong Hwa ^a   Wang, Hwei Ming ^c   Tsao, Chao Jung ^e   Hsu, Tzu Chi ^g   Chiu, Chang Fang ^d   Su, Wu Chou ^f   Wang, Jeng Yi ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adverse effect; Bevacizumab; Colorectal cancer; Expanded Access Program

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHINESE; CLINICAL ARTICLE; COMPASSIONATE USE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTESTINE PERFORATION; METASTATIC COLORECTAL CANCER; NAUSEA; NEUROPATHY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROTEINURIA; STOMATITIS; SURVIVAL TIME; TAIWAN; THROMBOEMBOLISM; THROMBOSIS; WOUND COMPLICATION; ADULT; AGED; ARTERIAL THROMBOEMBOLISM; CANCER GROWTH; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; FLUSHING; HOARSENESS; MALE; MULTICENTER STUDY; PROGRESSION FREE SURVIVAL; SKIN PRURITUS; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOICE CHANGE; VOICE DISORDER; VOMITING; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SAFETY; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84875671939     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000347228     Document Type: Article

References (16)

1. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 1999; 77:527-543.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Beva-cizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
3. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leu-covorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-1544.
4. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridge-water J, Cunningham D: Safety and efficacy of first-line bevacizumab with FOLFOX, XE-LOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20:1842-1847.
5. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as firstline treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523-3529.
6. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kab-binavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A: Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14:862-870.
7. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cas-sidy J: Bevacizumab in combination with ox-aliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-2019.
8. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U: Safety of bevaci-zumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010; 15:1179-1191.
9. Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, Feng S: Exploring racial differences in outcome and treatment for meta-static colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer 2012; 118:1083-1090.
10. Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hi-ronaka S, Onozawa Y: Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol 2009; 14:513-517.
11. Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O'Neill CA: Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27: 78-86.
12. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, Mc-Dermott MW, Parsa AT, Berger MS, Aghi MK: Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2011; 114:1609-1616.
13. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbina-var F, Novotny W, Sarkar S, Hurwitz H: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevaci-zumab. J Surg Oncol 2005; 91:173-180.
14. Hompes D, Ruers T: Review: incidence and clinical significance of bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol 2011; 37:737-746.
15. Sohmer H, Freeman S, Schmuel M: ABR threshold is a function of blood oxygen level. Hear Res 1989; 40:87-91.
16. Hapani S, Sher A, Chu D, Wu S: Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010; 79:27-38.